Acute iboga alkaloid effects on extracellular serotonin (5-HT) levels in nucleus accumbens and striatum in rats.
The iboga alkaloid, ibogaine, its metabolite, noribogaine, and the congener, 18-methoxycoronaridine (18-MC) have all been claimed to have anti-addictive properties in animal models, but the mechanisms underlying these effects are unclear. Ibogaine and noribogaine were shown to have affinity for the serotonin transporter, and inhibition of serotonin reuptake has been proposed to be involved in their anti-addictive actions. It is not known yet if 18-MC also has this property. In vivo microdialysis and HPLC (microbore) were used to determine acute changes in extracellular serotonin levels in nucleus accumbens (NAC) and striatum (STR) after both i.p. (40 mg/kg for all drugs) and i.v. (1-10 mg/kg for ibogaine and noribogaine) drug administration in awake freely moving female Sprague-Dawley rats (250-275 g). After i.p. administration, ibogaine, noribogaine and 18-MC had very different effects on extracellular serotonin levels in both NAC and STR: ibogaine elicited large increases (up to 25-fold in NAC and 10- fold in STR), noribogaine produced moderate increases (up to 8-fold in NAC and 5-fold in STR), and 18-MC had no effect in either brain region. These and other data suggest that (1) the serotonergic system may not be an essential factor in the anti-addictive actions of these drugs; (2) ibogaine (or an unidentified metabolite) may release serotonin as well as inhibit its reuptake; (3) stimulation of the ascending serotonergic system may mediate ibogaine's hallucinogenic effect; and (4) 18-MC probably has no affinity for the serotonin transporter, and is unlikely to be a hallucinogen.
Wei
D
D
Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY 12208, USA.
Maisonneuve
I M
IM
Kuehne
M E
ME
Glick
S D
SD
D000818:Animals; D003342:Corpus Striatum / Q000378:metabolism*; D005110:Extracellular Space / Q000378:metabolism; D005260:Female; D006213:Hallucinogens / Q000737:chemistry / Q000494:pharmacology*; D007050:Ibogaine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D017551:Microdialysis; D009714:Nucleus Accumbens / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012701:Serotonin / Q000737:chemistry / Q000378:metabolism*; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology
D006213:Hallucinogens; D012701:Serotonin; D007050:Ibogaine; C094385:noribogaine; C103345:18-methoxycoronaridine